| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2853
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1652
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-32 |
| filingDate |
2011-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2013-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2013525417-A |
| titleOfInvention |
Sustained release pharmaceutical composition of brivaracetam |
| abstract |
The present invention relates to a sustained release pharmaceutical composition comprising brivaracetam or a pharmaceutically acceptable derivative thereof. Further disclosed is a sustained release pharmaceutical composition comprising a core and a coating agent surrounding the core, wherein the core includes brivaracetam or a pharmaceutically acceptable derivative thereof, A hydrophobic release control agent is included. The sustained release pharmaceutical composition includes brivaracetam or a pharmaceutically acceptable derivative thereof and a hydrophobic release control agent, wherein the composition is a USP apparatus in 900 ml of pH 6 phosphate buffer solution. At least 80% brivaracetam elutes between about 7 and about 24 hours as measured using type II at 50 rpm and 37 ° C. Also disclosed is a sustained release pharmaceutical composition useful for the treatment of epilepsy and symptomatic myoclonus comprising brivaracetam or a pharmaceutically acceptable derivative thereof and a hydrophobic release controlling agent. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114146062-A |
| priorityDate |
2010-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |